Literature DB >> 7544887

Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.

L Q Sun1, L Wang, W L Gerlach, G Symonds.   

Abstract

The structural motif formed between a hammerhead ribozyme and its substrate consists of three RNA double helices in which the sequence 5' to the XUY is termed helix I and the sequence 3' to the XUY helix III. Two hammerhead ribozymes targeted to the tat gene of HIV-1SF2 were designed to study target specificity and the potential effect of helix I mismatch on ribozyme efficacy both in vitro and in vivo. The first ribozyme (Rz1) targeted to the 5' splicing region of the tat gene was designed to cleave GUC*A. In HIV-1IIIB the A is changed to a G. The second ribozyme (Rz2) was targeted to the translational initiation region of the tat gene which is highly conserved among a variety of HIV-1 isolates, including both HIV-1SF2 and HIV-1IIIB. In vitro cleavage studies demonstrated that Rz1 efficiency cleaved HIV-1SF2 substrate RNA, but not HIV-1IIIB, presumably due to the base change from A to G. In contrast, Rz2 cleaved HIV-1SF2 or HIV-1IIIB substrate with equal efficiency. Both ribozymes were cloned into the 3' untranslated region of the neomycin gene (neo) within the pSV2neo vector and transfected into the SupT1 human CD4+ T cell line. Following selection, stable transfectants were challenged with either HIV-1SF2 or HIV-1IIIB virus. While Rz1-expressing cells were significantly protected from HIV-1SF2 infection, they exhibited no protection when infected with HIV-1IIIB virus. In contrast, Rz2 was effective in inhibiting the replication of both HIV-1SF2 and HIV-1IIIB in SupT1 cells. Expression of both ribozymes in these cells was demonstrated by Northern analysis. RT-PCR sequencing analysis confirmed the respective HIV-1 target sequence integrity. These data demonstrate the importance of the first base pair distal to the XUY within helix I of the hammerhead structure for both in vitro and in vivo ribozyme activities and imply that the effectiveness of the anti-HIV-1 ribozymes against appropriate target sequences is due to their catalytic activities rather than any antisense effect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544887      PMCID: PMC307129          DOI: 10.1093/nar/23.15.2909

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  23 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  The trans-activator gene of HTLV-III is essential for virus replication.

Authors:  A G Fisher; M B Feinberg; S F Josephs; M E Harper; L M Marselle; G Reyes; M A Gonda; A Aldovini; C Debouk; R C Gallo
Journal:  Nature       Date:  1986 Mar 27-Apr 2       Impact factor: 49.962

3.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

4.  Construction of a series of several self-cleaving RNA duplexes using synthetic 21-mers.

Authors:  M Koizumi; S Iwai; E Ohtsuka
Journal:  FEBS Lett       Date:  1988-02-15       Impact factor: 4.124

5.  Hints for direct sequencing of PCR-generated single-stranded DNA.

Authors:  R C Nichols; N Raben
Journal:  Biotechniques       Date:  1994-09       Impact factor: 1.993

6.  The influence of imperfectly paired helices I and III on the catalytic activity of hammerhead ribozymes.

Authors:  M Zoumadakis; W J Neubert; M Tabler
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

7.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Authors:  P C Zamecnik; J Goodchild; Y Taguchi; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.

Authors:  M Yu; J Ojwang; O Yamada; A Hampel; J Rapapport; D Looney; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.

Authors:  L Q Sun; D Warrilow; L Wang; C Witherington; J Macpherson; G Symonds
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

View more
  17 in total

1.  Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.

Authors:  A A Mir; T J Lockett; P Hendry
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.

Authors:  M Y Chang; S J Won; H S Liu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 3.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

4.  Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase.

Authors:  H Kawasaki; J Ohkawa; N Tanishige; K Yoshinari; T Murata; K K Yokoyama; K Taira
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

Review 5.  Message therapy: gene therapy that targets mRNA sequence and stability.

Authors:  K F Kozarsky; L A Couture
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

Review 6.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

7.  Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site.

Authors:  B Kumar; Madhu Khanna; P Kumar; V Sood; R Vyas; A C Banerjea
Journal:  Mol Biotechnol       Date:  2012-05       Impact factor: 2.695

8.  Design and analysis of hammerhead ribozyme activity against an artificial gene target.

Authors:  James R Carter; Pruksa Nawtaisong; Velmurugan Balaraman; Malcolm J Fraser
Journal:  Methods Mol Biol       Date:  2014

9.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

10.  Selective DNAzyme-mediated cleavage of AChR mutant transcripts by targeting the mutation site or through mismatches in the binding arm.

Authors:  Amr Abdelgany; John Ealing; Matthew Wood; David Beeson
Journal:  J RNAi Gene Silencing       Date:  2005-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.